7498 Results (Page 286 of 300)
Pharmaceuticals Markets Research Reports
Singapore Periodontal Therapeutics Market Analysis
The Singapore Periodontal Therapeutics Market was valued at $1.1 Mn in 2023 and is predicted to grow at a CAGR of 7.8% from 2023 to 2030, to $1.8 Mn by 2030. Singapore Periodontal Therapeutics Market is growing due to Aging population, Rise in Demand for Non-surgical Periodontal Therapies, and Prevalence of periodontitis. The market is primarily dominated by players such as Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, Sun Pharmaceutical Industries Ltd, Tokyo Chemical Industry Co. Ltd., and Bausch Health Companies Inc.
Germany Cancer Induced Bone Disease Therapeutics Market Analysis
The Germany Cancer Induced Bone Disease Therapeutics Market was valued at $48 Mn in 2022 and is predicted to grow at a CAGR of 4% from 2023 to 2030, to $65 Mn by 2030. The key drivers of this industry include the rising prevalence of different cancers, advancements in diagnostics, and a robust healthcare system. The industry is primarily dominated by players such as Amgen, Novartis, Pfizer, Roche, Eli Lilly, Pharmalucence, and Bayer, among others.
Vietnam Periodontal Therapeutics Market Analysis
The Vietnam Periodontal Therapeutics Market was valued at $4.4 Mn in 2023 and is predicted to grow at a CAGR of 7.43% from 2023 to 2030, to $7.2 Mn by 2030. Vietnam Periodontal Therapeutics Market is growing due to Rising Awareness About Dental Hygiene, Economic Growth and Rising Disposable Income and Advancements in Treatment Technologies. The market is primarily dominated by players such as Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, Sun Pharmaceutical Industries Ltd, Tokyo Chemical Industry Co. Ltd., and Bausch Health Companies Inc.
Brazil Chronic Cough Therapeutics Market Analysis
Brazil Chronic Cough Therapeutics Market was valued at $158 Mn in 2022 and is estimated to reach $316 Mn in 2030, exhibiting a CAGR of 9.1% during the forecast period. The main driver behind the growth of the chronic cough therapeutics market is the extensive prevalence of chronic respiratory infections, often signaled by the occurrence of chronic cough. Presently, key participants in this market consist of GlaxoSmithKline (GSK), Pfizer, McNeil Consumer Healthcare (Johnson & Johnson), Procter & Gamble (P&G), Reckitt Benckiser Group, Perrigo Company, Medtech Products Inc., Bionpharma Inc., A. Vogel Canada Inc., and Jamieson Laboratories.
Egypt Periodontal Therapeutics Market Analysis
The Egypt Periodontal Therapeutics Market was valued at $2.4 Mn in 2023 and is predicted to grow at a CAGR of 8.7% from 2023 to 2030, to $4.4 Mn by 2030. Egypt Periodontal Therapeutics Market is growing due to Rising Awareness About Dental Hygiene, Prevalence of periodontitis and Advancements in Treatment Technologies. The market is primarily dominated by players such as Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, Sun Pharmaceutical Industries Ltd, Tokyo Chemical Industry Co. Ltd., and Bausch Health Companies Inc.
South Africa Periodontal Therapeutics Market Analysis
The South Africa Periodontal Therapeutics Market was valued at $5.7 Mn in 2023 and is predicted to grow at a CAGR of 8.43% from 2023 to 2030, to $10 Mn by 2030. South Africa Periodontal Therapeutics Market is growing due to Increasing Awareness Dental Hygiene, periodontitis Prevalence, and Advancing Treatment Technologies. The market is primarily dominated by players such as Dental365, Smile Dental, The Dental Spa, Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, and Sun Pharmaceutical Industries Ltd.
China Chronic Cough Therapeutics Market Analysis
China Chronic Cough Therapeutics Market was valued at $506 Mn in 2022 and is estimated to reach $1054 Mn in 2030, exhibiting a CAGR of 9.6% during the forecast period. The key driver behind the growth of the chronic cough therapeutics market is the prevalent occurrence of chronic respiratory infections, often identified by persistent coughing. Leading participants in this market presently include Hengan Group, Guangzhou Pharmaceutical Holdings, Shanghai Fosun Pharmaceutical, Beijing Tongrentang Group, Merck, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and GlaxoSmithKline.
Kenya Periodontal Therapeutics Market Analysis
The Kenya Periodontal Therapeutics Market was valued at $0.6 Mn in 2023 and is predicted to grow at a CAGR of 8.3% from 2023 to 2030, to $1.1 Mn by 2030. Kenya Periodontal Therapeutics Market is growing due to Rising Awareness About Dental Hygiene, Prevalence of periodontitis, and Rising Disposable Income. The market is primarily dominated by players such as Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, Sun Pharmaceutical Industries Ltd, Tokyo Chemical Industry Co. Ltd., and Bausch Health Companies Inc.
Egypt Chronic Cough Therapeutics Market Analysis
Egypt Chronic Cough Therapeutics Market was valued at $18 Mn in 2022 and is estimated to reach $37 Mn in 2030, exhibiting a CAGR of 9.6% during the forecast period. The predominant factor driving the growth of the chronic cough therapeutics market is the prevalent occurrence of persistent coughing associated with chronic respiratory infections. Leading entities in this sector currently include Pfizer, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, Merck & Co., AstraZeneca, Abbott Laboratories, Bayer AG, and Chiesi Farmaceutici.
India Periodontal Therapeutics Market Analysis
The India Periodontal Therapeutics Market was valued at $15.9 Mn in 2023 and is predicted to grow at a CAGR of 10.2% from 2023 to 2030, to $31.3 Mn by 2030. India Periodontal Therapeutics Market is growing due to Increasing disposable income and healthcare expenditure, Growing dental tourism, and Technological Advancements. The market is primarily dominated by players such as Sun Pharmaceutical Industries Ltd, Cipla, Pfizer Inc., Lupin Ltd, Teva Pharmaceuticals USA, and Bausch Health Companies Inc.
France Chronic Cough Therapeutics Market Analysis
France Chronic Cough Therapeutics Market was valued at $173 Mn in 2022 and is estimated to reach $300 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The primary factor propelling the expansion of the chronic cough therapeutics market is the widespread occurrence of chronic respiratory infections, commonly indicated by the presence of persistent coughing. Currently, prominent players in this market include Boiron, AstraZeneca, GlaxoSmithKline, Sanofi, Pfizer, Merck, Johnson & Johnson, Novartis, Teva Pharmaceutical Industries, and Pierre Fabre Laboratories.
Germany Chronic Cough Therapeutics Market Analysis
Germany Chronic Cough Therapeutics Market was valued at $231 Mn in 2022 and is estimated to reach $376 Mn in 2030, exhibiting a CAGR of 6.3% during the forecast period. The primary factor propelling the expansion of the chronic cough therapeutics market is the widespread occurrence of chronic respiratory infections, commonly indicated by the presence of persistent coughing. Currently, prominent players in this market include Boiron, AstraZeneca, GlaxoSmithKline, Sanofi, Pfizer, Merck, Johnson & Johnson, Novartis, Teva Pharmaceutical Industries, and Pierre Fabre Laboratories.
Indonesia Chronic Cough Therapeutics Market Analysis
Indonesia Chronic Cough Therapeutics Market was valued at $38 Mn in 2022 and is estimated to reach $70 Mn in 2030, exhibiting a CAGR of 8.1% during the forecast period. The key driver behind the growth of the chronic cough therapeutics market is the prevalent occurrence of chronic respiratory infections, often identified by persistent coughing. Leading participants in this market presently include Kalbe Farma, Sanofi, Bristol-Myers Squibb, PT Merck Sharp & Dohme, PT Pfizer, AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and GlaxoSmithKline.
Japan Chronic Cough Therapeutics Market Analysis
Japan Chronic Cough Therapeutics Market was valued at $392 Mn in 2022 and is estimated to reach $758 Mn in 2030, exhibiting a CAGR of 8.6% during the forecast period. The key driver behind the growth of the chronic cough therapeutics market is the prevalent occurrence of chronic respiratory infections, often identified by persistent coughing. Leading participants in this market presently include Eisai Co., Taisho Pharmaceutical Co., Shionogi & Co., Daiichi Sankyo Co., Sumitomo Dainippon Pharma Co., AstraZeneca, Boehringer Ingelheim, Chiesi, Novartis and GlaxoSmithKline.
Canada Hypersomnia Therapeutics Market Analysis
The Canada Hypersomnia Therapeutics Market was valued at $184.00 Mn in 2023 and is predicted to grow at a CAGR of 4.5% from 2023 to 2030, to $250.40 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Jazz Pharmaceuticals, Teva, Takeda, and Avadel Pharmaceuticals among others.
Kenya Chronic Cough Therapeutics Market Analysis
Kenya Chronic Cough Therapeutics Market was valued at $4 Mn in 2022 and is estimated to reach $9 Mn in 2030, exhibiting a CAGR of 9.2% during the forecast period. The primary catalyst propelling the expansion of the chronic cough therapeutics market is the widespread prevalence of persistent coughing linked to chronic respiratory infections. Key players in this industry comprise Pfizer, GlaxoSmithKline, Johnson & Johnson, Novartis, Sanofi, Merck & Co., AstraZeneca, Abbott Laboratories, Bayer AG, and Chiesi Farmaceutici.
US Hypersomnia Therapeutics Market Analysis
The US Hypersomnia Therapeutics Market was valued at $966 Mn in 2023 and is predicted to grow at a CAGR of 2.50% from 2023 to 2030, to $1,148.27 Mn by 2030. The key drivers of this industry include increasing awareness, lifestyle changes, expanding geriatric population, and early detection. The key players in the industry are Pfizer, Johnson & Johnson, Merck, GSK, and Sanofi among others.
Malaysia Chronic Cough Therapeutics Market Analysis
Malaysia Chronic Cough Therapeutics Market was valued at $10 Mn in 2022 and is estimated to reach $19 Mn in 2030, exhibiting a CAGR of 8.3% during the forecast period. The primary factor fuelling the expansion of the chronic cough therapeutics market is the widespread prevalence of chronic respiratory infections, frequently characterized by persistent coughing. Key players in this industry at present comprise Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Hikma Pharmaceuticals, and Abbott Laboratories.
Saudi Arabia Hypersomnia Therapeutics Market Analysis
The Saudi Arabia Hypersomnia Therapeutics Market was valued at $184.89 Mn in 2023 and is predicted to grow at a CAGR of 6.0% from 2023 to 2030, to $278.01 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Pfizer, Sanofi, Teva, GSK, and Novartis among others.
Philippines Chronic Cough Therapeutics Market Analysis
Philippines Chronic Cough Therapeutics Market was valued at $14 Mn in 2022 and is estimated to reach $27 Mn in 2030, exhibiting a CAGR of 8.6% during the forecast period. The primary factor fuelling the expansion of the chronic cough therapeutics market is the widespread prevalence of chronic respiratory infections, frequently characterized by persistent coughing. Key players in this industry at present comprise Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Hikma Pharmaceuticals, and Abbott Laboratories.
UAE Hypersomnia Therapeutics Market Analysis
The UAE Hypersomnia Therapeutics Market was valued at $41.83 Mn in 2023 and is predicted to grow at a CAGR of 7.50% from 2023 to 2030, to $69.39 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Teva, Jazz Pharmaceuticals, and Neopharma among others.
Saudi Arabia Chronic Cough Therapeutics Market Analysis
Saudi Arabia Chronic Cough Therapeutics Market was valued at $107 Mn in 2022 and is estimated to reach $223 Mn in 2030, exhibiting a CAGR of 9.6% during the forecast period. The primary factor fuelling the expansion of the chronic cough therapeutics market is the widespread occurrence of chronic respiratory infections, as the presence of such conditions is frequently indicated by chronic cough. Currently, major players in this market include GlaxoSmithKline (GSK), Pfizer, McNeil Consumer Healthcare (Johnson & Johnson), Procter & Gamble (P&G), Reckitt Benckiser Group, Perrigo Company, Medtech Products Inc., Bionpharma Inc., A. Vogel Canada Inc., and Jamieson Laboratories.
Brazil Hypersomnia Therapeutics Market Analysis
The Brazil Hypersomnia Therapeutics Market was valued at $142.96 Mn in 2023 and is predicted to grow at a CAGR of 5.0% from 2023 to 2030, to $201.17 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Teva, Takeda, and Merck, Jazz Pharmaceuticals among others.
Singapore Chronic Cough Therapeutics Market Analysis
Singapore Chronic Cough Therapeutics Market was valued at $8 Mn in 2022 and is estimated to reach $15 Mn in 2030, exhibiting a CAGR of 8.7% during the forecast period. The predominant factor driving the growth of the chronic cough therapeutics market is the prevalent occurrence of persistent coughing associated with chronic respiratory infections. Leading entities in this sector currently include Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, AstraZeneca, Boehringer Ingelheim, Teva Pharmaceuticals, Hikma Pharmaceuticals, and Abbott Laboratories.
Mexico Hypersomnia Therapeutics Market Analysis
The Mexico Hypersomnia Therapeutics Market was valued at $13.80 Mn in 2023 and is predicted to grow at a CAGR of 4.5% from 2023 to 2030, to $18.78 Mn by 2030. The key drivers of this industry include the rising prevalence of sleep disorders, expanding geriatric population, early detection, and advancement in diagnostic tools. The key players in the industry are Sanofi, Pfizer, Merck, and Laboratorios Sanfer among others.
